A624E35EC511A22EA96BE3E7265ABF72
Clinical Research in
Mauritius
https://leaux.net/URLS/General/guidelines-clinical-research-in-mauritius.pdf
http://leaux.net/URLS/ConvertAPI Text Files/78952CF4F3D51701C5AD100D7AE1A490.en.txt
Examining the file media/Synopses/78952CF4F3D51701C5AD100D7AE1A490.html:
This file was generated: 2020-03-05 05:20:58
Indicators in focus are typically shown highlighted in yellow; |
Peer Indicators (that share the same Vulnerability association) are shown highlighted in pink; |
"Outside" Indicators (those that do NOT share the same Vulnerability association) are shown highlighted in green; |
Trigger Words/Phrases are shown highlighted in gray. |
Link to Orphaned Trigger Words (Appendix (Indicator List, Indicator Peers, Trigger Words, Type/Vulnerability/Indicator Overlay)
Applicable Type / Vulnerability / Indicator Overlay for this Input
Political / Trade Union Membership
Searching for indicator union:
(return to top)
p.000004:
p.000004: YES
p.000004:
p.000004: Issue of Amended Trial License by the CRRC
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000005: 5
p.000005:
p.000005:
p.000005: III. GOOD CLINICAL PRACTICE
p.000005:
p.000005:
p.000005: - Clinical trials shall be conducted in accordance with the conditions and principles of good clinical practice.
p.000005: - The rights, safety and well-being of a subject shall prevail over the interests of science and society.
p.000005: - Every sponsor shall ensure that any person involved in conducting a clinical trial is qualified by education,
p.000005: training and experience to perform his tasks.
p.000005: - Every sponsor and investigator shall comply with guidelines prepared or approved by the Council.
p.000005:
p.000005: The Clinical Research Regulatory Council and Ethics Committee are strictly following the ICH European Guidelines to
p.000005: permit the conduct of Clinical Research in Mauritius:
p.000005:
p.000005: • ICH E6: Good Clinical Practice: Consolidated guideline
p.000005:
p.000005: • ICH Harmonised Tripartite Guideline E8: General Considerations for Clinical Trials
p.000005:
p.000005: This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to
p.000005: consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is
p.000005: recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
p.000005:
p.000005: • ICH Harmonised Tripartite Guideline E10: Choice of Control Group and related issues in Clinical Trials
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000006: 6
p.000006:
p.000006:
p.000006: IV. TRIAL MASTER FILE & ARCHIVING
p.000006:
p.000006: Every sponsor shall keep a trial master file for a clinical trial in respect of which he holds a trial licence.
p.000006:
p.000006: A sponsor shall make the trial master file readily available at all reasonable times for inspection by the Council or
p.000006: any person appointed by the sponsor to audit the arrangements for the clinical trial.
p.000006:
p.000006: The trial master file shall at all times comprise documents which –
p.000006:
p.000006: - enable both the conduct of the clinical trial and the quality of the data produced to be evaluated;
p.000006:
p.000006: - show whether the clinical trial has been conducted in compliance with –
p.000006:
p.000006: (i) this Act and regulations made under it; and
p.000006:
p.000006: (ii) the guidelines referred to in section 4(f); and
p.000006:
p.000006: - contain information specific to each phase of the clinical trial.
p.000006:
p.000006: A sponsor shall keep, for not less than 15 years after the completion of a clinical trial, the trial master file which
p.000006: shall be –
p.000006:
p.000006: - readily available at all reasonable times to the Council; and
p.000006:
p.000006: - complete and legible.
p.000006:
p.000006: V. PROGRESS & COMPLETION OF CLINICAL TRIAL REPORTS
p.000006:
...
Health / Health
Searching for indicator health:
(return to top)
p.000008: VIII. CHAIRPERSONS OF THE REGULATORY BODIES
p.000008: 8
p.000008: IX. CONTACT
p.000009: 9
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009:
p.000009: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000001: 1
p.000001:
p.000001: INTRODUCTION
p.000001: The Government of Mauritius has introduced the Clinical Trials Act with the aim to provide the legal framework to
p.000001: conduct clinical trials.
p.000001:
p.000001: With the Clinical Trials Act adoption by the National Assembly on the 19 April 2011, Mauritius has seen a major
p.000001: development in its life sciences and research sector. The Act provides the legal framework for the conduct of
p.000001: clinical trials for the purpose of discovering or verifying the effects of investigational medicinal
p.000001: products. Clinical research conducted in Mauritius can provide solutions to a broad range of genetic, infectious and
p.000001: lifestyle diseases like diabetes, cardiovascular diseases, cancer, hypertension amongst others prevailing in
p.000001: Mauritius and countries of the region.
p.000001:
p.000001: The Clinical Trials Act provides for the setting up of a:
p.000001:
p.000001:
p.000001: - Clinical Research Regulatory Council (CRRC) responsible for the regulation and control of trial licenses being
p.000001: issued.
p.000001: - Ethics Committee (EC) to advise the CRRC regarding welfare, safety, health and protection of human
p.000001: subjects participating in clinical trials.
p.000001: - Pharmacovigilance Committee (PC) to monitor all clinical trials being performed and ensure Good
p.000001: Clinical Practice (GCP).
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001:
p.000001: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000002: 2
p.000002:
p.000002:
p.000002:
p.000002:
p.000002: I. APPLICATION FOR A TRIAL LICENSE
p.000002:
p.000002: Application for Trial Licence with the Clinical Research Regulatory Council (CRRC) accompanied by the prescribed
p.000002: application fee and the required documents*
p.000002:
p.000002:
p.000002:
p.000002:
p.000002: Are all documents available?
p.000002:
p.000002:
p.000002: YES
p.000002:
p.000002: Initial evaluation by the Clinical Research Regulatory Council
p.000002:
p.000002:
p.000002:
p.000002: Submission of the application and documents to the Ethics Committee (EC) for approval
p.000002: An Application shall be accompanied by 25 copies of:
p.000002: - A protocol;
p.000002: - An investigator’s brochure;
p.000002: - A brief C.V of every investigator;
p.000002: - A Certificate of Good Manufacturing Practice (GMP) and a Certificate of Pharmaceutical Product (COPP) in
p.000002: relation to every investigational medicinal product from its country of origin; and
p.000002: - The separate and different forms to be used for the purposes of patient and subject information, informed
p.000002: consent, recruitment of subjects, adverse event reports and adverse reaction reports.
p.000002:
p.000002:
p.000002:
p.000002:
p.000002: Approval from the EC & CRRC?
p.000002:
p.000002: YES
p.000002:
p.000002:
p.000002:
p.000002:
p.000002: Written notice of decision to the sponsor
p.000002:
p.000002: Payment of the Prescribed License Fee
p.000002:
p.000002:
p.000002:
p.000002: Application granted by the CRRC
p.000002:
p.000002:
p.000002:
p.000002:
p.000002: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000003: 3
p.000003:
p.000003:
p.000003:
p.000003: The sponsor shall also provide -
p.000003:
p.000003: - information as to the quantity of every investigational medicinal product to be used in the clinical trial;
p.000003: - information relating to the measures to be taken for the health, welfare, safety and protection of subjects;
p.000003: - information relating to financial aspects of the clinical trial, in particular -
p.000003:
p.000003: i sources of funding for the clinical trial and information on the financial or other interests of the sponsor relevant
p.000003: to the clinical trial;
p.000003: ii the arrangements for the reimbursement of expenses incurred by the subjects;
p.000003:
p.000003: iii any provision for compensation in the event of injury or death resulting from the clinical trial, including details
p.000003: of any insurance cover to be contracted for the protection of subjects;
p.000003: iv details of any insurance or indemnity to cover the liability of the sponsor and investigator;
p.000003: v summary details of any financial arrangements between -
p.000003:
p.000003: (A) the sponsor and the investigator; and
p.000003:
p.000003: (B) the sponsor and the owner or occupier of the site;
p.000003:
p.000003: - information relating to the anticipated benefits and risks of the clinical trial;
p.000003: - information relating to the location, structure and amenities of any site where the clinical trial is to be
p.000003: conducted; and
p.000003: - such other information as the Council may require.
p.000003:
p.000003:
p.000003:
p.000003: If all the relevant documents are provided, a trial licence is deliverable within 60 days.
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000004: 4
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
...
p.000007:
p.000007: VIII. CHAIRPERSONS OF THE REGULATORY BODIES
p.000007:
p.000007: Clinical Research Regulatory Council Dr S.K. Surrun, Consultant, City Clinic
p.000007: Ethics Committee Judge Satyabhoosun Domah, Judge,
p.000007: Supreme Court
p.000007: Pharmacovigilance Committee Dr Jayanandra Dusowoth, Senior Specialist, SSRN
p.000007: Hospital
p.000007:
p.000007:
p.000007: All applications for Clinical Research must be addressed to:
p.000007:
p.000007: The Secretary – Mr Reesaul Clinical Research Regulatory Council
p.000007: Atchia Building Suffren Street Port Louis
p.000007:
p.000007:
p.000007: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000008: 8
p.000008:
p.000008:
p.000008:
p.000008: IX. CONTACT
p.000008:
p.000008: Foreign Contract Research Organisations (CROs) willing to setup in Mauritius, are invited to contact the
p.000008: Board of Investment (BOI).
p.000008: The BOI, the national investment promotion and facilitation agency of the Government of Mauritius, provides the
p.000008: following services free of charge:
p.000008:
p.000008: - Counseling on investment opportunities in Mauritius
p.000008: - Providing tailor made information for the setting up of a business in Mauritius
p.000008: - Organisation of meetings and site visits
p.000008: - Assistance in identification of joint venture partners
p.000008: - Assistance with site locations
p.000008: - Assistance for occupation permits, licenses and clearances.
p.000008:
p.000008:
p.000008: Mr. Nitin Pandea Director
p.000008: Tel: +230 203 3807
p.000008: Email: health@investmauritius.com
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008: Clinical Research in Mauritius Board of Investment November 7, 2011
...
Social / Educational
Searching for indicator education:
(return to top)
p.000003: conducted; and
p.000003: - such other information as the Council may require.
p.000003:
p.000003:
p.000003:
p.000003: If all the relevant documents are provided, a trial licence is deliverable within 60 days.
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003:
p.000003: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000004: 4
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004: II. AMENDMENT OF A TRIAL LICENSE
p.000004:
p.000004: Written application to amend the protocol or any other document submitted to the CRRC accompanied by the Prescribed Fee
p.000004:
p.000004:
p.000004:
p.000004: CRRC shall refer the application to the EC for approval
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004: Approval from the EC & CRRC?
p.000004: Written notice of decision to the sponsor
p.000004:
p.000004: YES
p.000004:
p.000004: Issue of Amended Trial License by the CRRC
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004:
p.000004: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000005: 5
p.000005:
p.000005:
p.000005: III. GOOD CLINICAL PRACTICE
p.000005:
p.000005:
p.000005: - Clinical trials shall be conducted in accordance with the conditions and principles of good clinical practice.
p.000005: - The rights, safety and well-being of a subject shall prevail over the interests of science and society.
p.000005: - Every sponsor shall ensure that any person involved in conducting a clinical trial is qualified by education,
p.000005: training and experience to perform his tasks.
p.000005: - Every sponsor and investigator shall comply with guidelines prepared or approved by the Council.
p.000005:
p.000005: The Clinical Research Regulatory Council and Ethics Committee are strictly following the ICH European Guidelines to
p.000005: permit the conduct of Clinical Research in Mauritius:
p.000005:
p.000005: • ICH E6: Good Clinical Practice: Consolidated guideline
p.000005:
p.000005: • ICH Harmonised Tripartite Guideline E8: General Considerations for Clinical Trials
p.000005:
p.000005: This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to
p.000005: consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is
p.000005: recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
p.000005:
p.000005: • ICH Harmonised Tripartite Guideline E10: Choice of Control Group and related issues in Clinical Trials
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005:
p.000005: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000006: 6
p.000006:
p.000006:
p.000006: IV. TRIAL MASTER FILE & ARCHIVING
p.000006:
p.000006: Every sponsor shall keep a trial master file for a clinical trial in respect of which he holds a trial licence.
p.000006:
p.000006: A sponsor shall make the trial master file readily available at all reasonable times for inspection by the Council or
...
Social / Occupation
Searching for indicator occupation:
(return to top)
p.000007: 200,000
p.000007: Clinical trial (Phase IV) license fee
p.000007: 20,000
p.000007: Annual service fee
p.000007: 20,000
p.000007:
p.000007:
p.000007:
p.000007: VIII. CHAIRPERSONS OF THE REGULATORY BODIES
p.000007:
p.000007: Clinical Research Regulatory Council Dr S.K. Surrun, Consultant, City Clinic
p.000007: Ethics Committee Judge Satyabhoosun Domah, Judge,
p.000007: Supreme Court
p.000007: Pharmacovigilance Committee Dr Jayanandra Dusowoth, Senior Specialist, SSRN
p.000007: Hospital
p.000007:
p.000007:
p.000007: All applications for Clinical Research must be addressed to:
p.000007:
p.000007: The Secretary – Mr Reesaul Clinical Research Regulatory Council
p.000007: Atchia Building Suffren Street Port Louis
p.000007:
p.000007:
p.000007: Clinical Research in Mauritius Board of Investment November 7, 2011
p.000008: 8
p.000008:
p.000008:
p.000008:
p.000008: IX. CONTACT
p.000008:
p.000008: Foreign Contract Research Organisations (CROs) willing to setup in Mauritius, are invited to contact the
p.000008: Board of Investment (BOI).
p.000008: The BOI, the national investment promotion and facilitation agency of the Government of Mauritius, provides the
p.000008: following services free of charge:
p.000008:
p.000008: - Counseling on investment opportunities in Mauritius
p.000008: - Providing tailor made information for the setting up of a business in Mauritius
p.000008: - Organisation of meetings and site visits
p.000008: - Assistance in identification of joint venture partners
p.000008: - Assistance with site locations
p.000008: - Assistance for occupation permits, licenses and clearances.
p.000008:
p.000008:
p.000008: Mr. Nitin Pandea Director
p.000008: Tel: +230 203 3807
p.000008: Email: health@investmauritius.com
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008:
p.000008: Clinical Research in Mauritius Board of Investment November 7, 2011
...
Orphaned Trigger Words
Appendix
Indicator List
Indicator | Vulnerability |
education | Educational |
health | Health |
occupation | Occupation |
union | Trade Union Membership |
Indicator Peers (Indicators in Same Vulnerability)
Trigger Words
consent
ethics
protection
welfare
Applicable Type / Vulnerability / Indicator Overlay for this Input